June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Exploratory Analysis of Persistent Macular Thickening Following Intravitreal Ranibizumab for Center-Involved Diabetic Macular Edema
Author Affiliations & Notes
  • Raj Maturi
    Ophthalmology, Midwest Eye Institute, Indianapoils, IN
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • Footnotes
    Commercial Relationships Raj Maturi, Allergan (C), Allergan (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1732. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raj Maturi, Diabetic Retinopathy Clinical Research Network; Exploratory Analysis of Persistent Macular Thickening Following Intravitreal Ranibizumab for Center-Involved Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1732.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine the frequency of continued persistent DME after 24 weeks of intravitreous ranibizumab injections and to assess the impact of persistent DME on long term visual acuity in a DRCR.net randomized clinical trial comparing ranibizumab with prompt or deferred laser with laser or triamcinolone plus laser

Methods: Eyes had best-corrected visual acuity of 20/32 to 20/320 and centered involved DME at baseline. Eyes were randomly assigned to intravitreous ranibizumab with prompt or deferred (≥24 weeks) focal/grid laser. Follow-up exams were every 4 weeks through week 52 and every 4 to 16 weeks through 3 years and included a retreatment protocol. 117 eyes (32.4%) of 361 participants randomly assigned to ranibizumab had persistent DME (central subfield thickness [CST] ≥250μm on time domain optical coherence tomography [OCT]) through the 24-week visit despite at least four intravitreous injections of ranibizumab. Cumulative probabilities of “chronic persistent DME” (failure to achieve CST <250 um and at least a 10% reduction from the 24-week visit on 2 consecutive study visits) were determined by life-table analyses

Results: The cumulative probability of chronic persistent DME among eyes with persistent DME at the 24-week visit was 85%, 58%, and 42% (99% CI: 30% to 54%) at the 52-, 104-, and 156-week visits, respectively. Of the eyes with persistent DME at 24 weeks, the median visual acuity letter score at one year improved from randomization by 8 letters for eyes with and without chronic persistent DME at 1 year. Visual acuity improved at 3 years by a median of 5 letters and 12 letters from randomization, in eyes with and without chronic persistent DME at 3 years respectively. Among eyes with chronic persistent edema through 3 years, 43% gained ≥10 letters while 13% lost ≥10 letters from the randomization visit.

Conclusions: These data suggest approximately one-third of eyes treated for DME with intravitreous ranibizumab have persistent central-involved DME six months after initiating treatment. Approximately half of these eyes have chronic persistent central-involved DME through 3 years. Longer-term visual acuity outcomes appear to be better among eyes without chronic persistent DME. Nevertheless, substantial (≥2 line) loss of visual acuity is uncommon at three years, even when central-involved DME persists.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.